Blood far forward

Andrew, P.; Pidcoke, Heather F.; DePasquale, Marc; Rappold, Joseph F.; Glassberg, Elon; Eliassen, Håkon Skogrand; Bjerkvig, Christopher; Fosse, Theodor K.; Kane, Shawn F.; Thompson, Patrick; Sikorski, Robert; Miles, Edward F.; Fisher, Andrew D; Ward, Kevin R.; Spinella, Philip C.; Strandenes, Geir

doi:10.1097/ta.0000000000000626

Cited by 36 publications

(21 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, these results may not be as applicable in rural America and the developing world, where RBCs, thawed plasma and platelets are in limited supply, limiting access to therapies, such as damage control resuscitation. To improve trauma care in these settings, novel blood products 10, 11 , such as lyophilized plasma 12 , and freeze dried platelets are being developed but are not yet available in the United States.…”

Section: Discussionmentioning

confidence: 99%

Damage-control resuscitation and emergency laparotomy

Perl

Cook

Watson

et al. 2016

Journal of Trauma and Acute Care Surgery

View full text Add to dashboard Cite

Background The Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial has demonstrated that damage control resuscitation, a massive transfusion strategy targeting a balanced delivery of plasma-platelet-RBC in a ratio of 1:1:1, results in improved survival at 3 hours and a reduction in deaths due to exsanguination in the first 24 hours compared to a 1:1:2 ratio. In light of these findings, we hypothesized that patients receiving 1:1:1 ratio would have improved survival after emergency laparotomy. Methods Severely injured patients predicted to receive a massive transfusion admitted to 12 level I North American trauma centers were randomized to 1:1:1 versus 1:1:2 as described in the PROPPR trial. From these patients, the subset that underwent an emergency laparotomy, defined previously in the literature as laparotomy within 90 minutes of arrival, were identified. We compared rates and timing of emergency laparotomy as well as post-surgical survival at 24-hours and 30-days. Results Of the 680 enrolled patients, 613 underwent a surgical procedure, 397 underwent a laparotomy, and 346 underwent an emergency laparotomy. The percentages of patients undergoing emergency laparotomy were 51.5% (174/338) and 50.3% (172/342) for 1:1:1 and 1:1:2, respectively (p=0.20). Median time to laparotomy was 28 minutes in both treatment groups. Among patients undergoing an emergency laparotomy, the proportions of patients surviving to 24 hours and 30 days were similar between treatment arms, 24-hour survival was 86.8% (151/174) for 1:1:1 and 83.1% (143/172) for 1:1:2 (p=0.29), and 30-day 79.3% (138/174) for 1:1:1 and 75.0% (129/172) for 1:1:2 (p=0.30). Conclusions We found no evidence that resuscitation strategy affects whether a patient requires an emergency laparotomy, time to laparotomy, or subsequent survival. Level of Evidence Level IV, therapeutic study.

show abstract

Section: Discussionmentioning

confidence: 99%

Damage-control resuscitation and emergency laparotomy

Perl

Cook

Watson

et al. 2016

Journal of Trauma and Acute Care Surgery

View full text Add to dashboard Cite

show abstract

“…PFC has a half-life of 3 to 6 hours, whereas FTPA stays in the body for months 25 . People must breathe pure oxygen through a mask or in a hyperbaric chamber for it to carry a sufficient amount of oxygen 26 . Red blood cells can carry more oxygen at 37°C than Fluosol-DA, which can only carry about 7.2 percent.…”

Section: Generations Of Pfcmentioning

confidence: 99%

Untitled

2023

IJPSR

View full text Add to dashboard Cite

In hospitals, blood transfusions are a common occurrence. Because blood-related products are limited and have a range of adverse side effects, researchers have worked on artificial blood components for nearly 40 years. It is crucial to develop effective and selective alternatives for natural blood products. Artificial blood is a useful idea in transfusion medicine wherein clearly defined compounds perform the functions of oxygen transport and distribution in the body to enhance allogeneic human blood transfusion. Several molecules are created over a long period of time to achieve this goal, and ongoing modifications are performed in the pursuit of the ideal blood substitute. Currently, perfluorocarbons (PFC) or haemoglobin derived from outdated human/bovine blood (Hemoglobin Based Oxygen Carriers; HBOC) are used to manufacture artificial blood. The focus of this review paper is to provide a comprehensive view of different developed products that can be used as blood alternatives.INTRODUCTION: Blood is a type of connective tissue made up of white blood cells, red blood cells, platelets, and plasma. It serves several purposes in the body. Plasma is an extracellular material composed of water, salts, and various proteins that, along with platelets, promotes blood clotting. Membrane proteins react with air and harden to prevent further bleeding. White blood cells are in charge of defending the body. They seek out invading organisms or materials and work to reduce their impact on the body. The red appearance of blood is caused by red cells. One billion red blood cells can be found in just two drops of blood.

show abstract

“…The need for refrigerated conditions creates major logistical challenges when donor blood is needed in austere and remote battlefield or civilian locations. [4][5][6] Also, both RBCs and platelets develop storage lesions over time affecting their stability, physiology as well as their in vivo circulation time. 7,8 For example, while RBCs can circulate in the bloodstream for about 120 days, this time is reduced to only 28 days for donor RBCs.…”

Section: Introductionmentioning

confidence: 99%